Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and for the month of July.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.
Epizyme Inc. (NASDAQ: EPZM) is expected to issue an update on its partial clinical hold of tazemetostat following reports of a child with advanced poorly differentiated chordoma, a rare bone cancer, developing a secondary T-cell lymphoma. Trial enrollment outside the United States has not been affected. Shares of Epizyme closed Friday at $13.55, in a 52-week range of $11.15 to $21.40 and with a consensus analyst target of $25.25.
Omeros Corp. (NASDAQ: OMER) is expected to release data from its Phase 2 study of OMS721/IgAN in patients not taking steroids (U.S. cohort). Shares of Omeros closed Friday at $18.14. The consensus analyst target is $36.40, and the 52-week range is $8.36 to $25.20.
Tesaro Inc. (NASDAQ: TSRO) is expected to issue an update on its regulatory discussions with FDA regarding niraparib in breast cancer. Shares of Omeros closed Friday at $44.47, with a consensus analyst target of $77.67 and a 52-week range of $38.40 to $143.45.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.
24/7 Wall St.Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.